Lirilumab
- Product Name
- Lirilumab
- CAS No.
- 1000676-41-4
- Chemical Name
- Lirilumab
- Synonyms
- Lirilumab;ONO-4483|||IPH2102;Lirilumab (anti-KIR);Research Grade Lirilumab;Research Grade Lirilumab(DHE43401)
- CBNumber
- CB23354241
- Formula Weight
- 0
- MOL File
- Mol file
Lirilumab Property
- form
- Liquid
- color
- Colorless to light yellow
Lirilumab Chemical Properties,Usage,Production
Uses
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research[1][2].
in vivo
Lirilumab (intravenous injection; 15 mg/kg; once) treatment enhances survival rate of mice injected with tumor[2].
| Animal Model: | Rag1KO-Tg KIR mice injected with tumor cells[2] |
| Dosage: | 15 mg/kg |
| Administration: | intravenous injection; 15 mg/kg; once |
| Result: | Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died. |
References
[1] Hanna GJ, et al. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Feb 1;28(3):468-478. DOI:10.1158/1078-0432.CCR-21-2635
[2] Kohrt HE, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014 Jan 30;123(5):678-86. DOI:10.1182/blood-2013-08-519199
Lirilumab Preparation Products And Raw materials
Raw materials
Preparation Products
Lirilumab Suppliers
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58
- Tel
- 16314854226
- info@bocsci.com
- Country
- United States
- ProdList
- 9923
- Advantage
- 65